Single- and Multiple-dose Pharmacokinetics of Oral Moxifloxacin and Clarithromycin, and Concentrations in Serum, Saliva and Faeces

References

• Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1619–24.
   Web of Science ®Google Scholar
• Dalhoff A, Petersen U, Endermann E. In vitro activity of Bay 12–8039, a new 8-methoxyquinolone. Chemotherapy 1996; 42: 410–25.
   Google Scholar
• MacGowan AP, Bowker KE, Holt HA, Wootton M, Reeves DS. Bay 12–8039, a new 8-methoxy-quinolone: comparative in vitro activity with nine other antimicrobials against anaerobic bacteria. J Antimicrob Chemother 1997; 40: 503–9.
   Google Scholar
• Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of Bay 12–8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101–6.
   Google Scholar
• Souli M, Wennersten CB, Eliopoulos GM. In vitro activity of Bay 12–8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. Int J Antimicrob Agents 1998; 10: 23–30.
   Google Scholar
• Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones Clin Infect Dis 1998; 27: 33–9.
   PubMed Web of Science ®Google Scholar
• Dalhoff A, Ullmann U. Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models. Eur J Clin Microbiol Infect Dis 1990; 9: 479–87.
   PubMed Web of Science ®Google Scholar
• Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12–8039), a new enantiomerically pure 8- methoxy quinolone. Antimicrob Agents Chemother 1999; 43: 2793–7.
   PubMed Web of Science ®Google Scholar
• Stass H, Kubitza D, Schuhly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin Pharmacokinet 2001; 40: 1–9.
   Google Scholar
• Beyer G, Hiemer-Bau M, Ziege S, Edlund C, Lode H, Nord CE. Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora. Eur J Microbiol Infect Dis 2000; 19: 548–50.
   PubMed Web of Science ®Google Scholar
• Edlund C, Beyer G, Hiemer-Bau M, Ziege S, Lode H, Nord CE. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis 2000; 32: 81–5.
   Google Scholar
• Staß H, Dalhoff A. Determination of BAY 12–8039, a new 8-methoxyquinolone, in human body fluids by high performance liquid chromatography with fluorescence detection using on-column focussing. J Chromat 1997; 702: 163–74.
   Google Scholar
• Borner K, Hartwig H, Lode H. Determination of clarithromycin and a metabolite in serum and urine by RPHPLC with coulometric detection. In: Reid E, Wilson ID, eds. Bioanalytical approaches for drugs, including antiasthmatics and metabolites. Methodol Surv Biochem Analysis 1992; 22: 137–40.
   Google Scholar
• Peloquin CA, Cumbo TJ, Nix DE, Sands M, Schentag JJ. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infection. Arch Intern Med 1989; 149: 2269–73.
   Google Scholar
• Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ. Development of a population pharmacokinetic model and optimal sampling strategy for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993; 37: 1065–72.
   Google Scholar
• Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073–81.
   PubMed Web of Science ®Google Scholar
• Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44: 2600–3.
   Google Scholar
• Staß H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43: 83–90.
   Google Scholar
• Staß H, Dalhoff A, Kubitza D, Schühly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxyquinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060–5.
   Google Scholar
• Müller M, Staß H, Brunner M, Möller JG, Lackner E, Eichler HG. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999; 43: 2345–9.
   PubMed Web of Science ®Google Scholar
• Fassbender M, Lode H, Schiller C, Andro R, Goetschi B, Borner K, Koeppe P. Comparative pharmacokinetics of macrolide antibiotics and concentrations achieved in polymorphonuclear leukocytes and saliva. Clin Microbiol Infect 1995; 1: 235–43.
   Google Scholar
• Barry AL, Thornsberry C, Jones RN. In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. Antimicrob Agents Chemother 1987; 31: 343–5.
   Google Scholar
• Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB. Comparative in vitro activities of new 14-, 15- and 16-membered macrolides. Antimicrob Agents Chemother 1988; 32: 1710–9.
   PubMed Web of Science ®Google Scholar